Rheonix Nets $12.6M to Develop PCR-based MDx Assays on Microfluidics Platform

The company will use the cash to continue developing in vitro diagnostic assays for its "chemistry and reagent device," or CARD — which integrates sample preparation, nucleic acid amplification, and endpoint detection all on a single microfluidics-based, point-of-care polymeric module.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.